全文获取类型
收费全文 | 2576篇 |
免费 | 191篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 108篇 |
妇产科学 | 61篇 |
基础医学 | 438篇 |
口腔科学 | 36篇 |
临床医学 | 224篇 |
内科学 | 605篇 |
皮肤病学 | 36篇 |
神经病学 | 200篇 |
特种医学 | 113篇 |
外科学 | 299篇 |
综合类 | 9篇 |
一般理论 | 1篇 |
预防医学 | 262篇 |
眼科学 | 25篇 |
药学 | 126篇 |
中国医学 | 5篇 |
肿瘤学 | 196篇 |
出版年
2023年 | 19篇 |
2022年 | 38篇 |
2021年 | 69篇 |
2020年 | 51篇 |
2019年 | 73篇 |
2018年 | 118篇 |
2017年 | 46篇 |
2016年 | 59篇 |
2015年 | 79篇 |
2014年 | 120篇 |
2013年 | 153篇 |
2012年 | 216篇 |
2011年 | 211篇 |
2010年 | 115篇 |
2009年 | 112篇 |
2008年 | 169篇 |
2007年 | 176篇 |
2006年 | 192篇 |
2005年 | 172篇 |
2004年 | 148篇 |
2003年 | 135篇 |
2002年 | 132篇 |
2001年 | 21篇 |
2000年 | 8篇 |
1999年 | 18篇 |
1998年 | 24篇 |
1997年 | 10篇 |
1996年 | 25篇 |
1995年 | 10篇 |
1994年 | 13篇 |
1993年 | 8篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1975年 | 2篇 |
1972年 | 2篇 |
排序方式: 共有2771条查询结果,搜索用时 15 毫秒
21.
Myriam Khlat Marie-Hélène Cazes Emmanuelle Génin Marguerite Guiguet 《Cancer epidemiology, biomarkers & prevention》2004,13(10):1660-1664
Case-control studies of genetic factors are prone to a special form of confounding called population stratification, whenever the existence of one or more subpopulations may lead to a false association, be it positive or negative. We quantify both the bias (in terms of confounding risk ratio) and the probability of false association (type I error) in the most unfavorable situation in which only one high-risk subpopulation is hidden within the studied population, considering different scenarios of population structuring and varying sample sizes. In accord with previous work, we find that the bias is likely to be small in most cases. In addition, we show that the same applies to the associated type I error whenever the subpopulation is small in proportion. For instance, when the hidden subpopulation makes up 5% of the entire population, with an allelic frequency of 0.25 (versus 0.10) and a disease rate that is double, then the estimated bias is 1.07 and the type I error associated with a sample of 500 cases and 500 controls is 8% (instead of 5%). We also show that the type I error is substantially greater for a rare allele (frequency of 0.1) than for a common allele (frequency of 0.5) and analyze the pattern of increase of vulnerability to stratification bias with sample size. Based on our findings, we may therefore conclude that with moderate sample sizes the type I error associated with population stratification remains very limited in most realistic scenarios. 相似文献
22.
Claire Joqueviel Véronique Gilard Robert Martino Myriam Malet-Martino Ulf Niemeyer 《Cancer chemotherapy and pharmacology》1997,40(5):391-399
Phosphorus-31 nuclear magnetic resonance spectroscopy was used to evaluate the stability of carboxycyclophosphamide (CXCP)
and carboxyifosfamide (CXIF) in human urine at pH 7.0 and 5.5 at 25°, 8°, −20°, and −80 °C. At 25 °C and pH 7.0, CXCP and
CXIF are relatively stable (≈10% degradation in 24 h). In contrast, they are much less stable at pH 5.5 (≈80% degradation
of CXIF and ≈50% degradation of CXCP in 24 h). The rate of degradation of CXCP and CXIF was a function of the storage temperature
of the urine samples but, even at −80 °C, was not negligible: ≈30% degradation for CXCP irrespective of pH and ≈40% and 50%
degradation for CXIF at pH 7.0 and 5.5, respectively, after storage for 6 months. CXCP was more stable than CXIF at either
pH (7.0 or 5.5) and at all storage temperatures (8°, −20°, or −80 °C) of the urine samples. CXCP and CXIF were more stable
at pH 7.0 than at pH 5.5, although this difference fell with decreasing temperatures to be almost negligible at −80 °C. To
ensure a true estimate of CXCP and CXIF levels, urine samples must be frozen and stored at −80 °C within a few hours of micturition.
CXCP and CXIF assays should also be carried out within 2 months and 1 month of storage, respectively.
Received: 13 July 1996 / Accepted: 20 January 1997 相似文献
23.
24.
Pilar Joannon Iris Oviedo Myriam Campbell Juan Tordecilla 《Pediatric blood & cancer》2004,43(1):17-22
BACKGROUND: The objectives of this study were: (1) to analyze the relation of serum methotrexate (MTX) concentration with creatinine clearance, (2) to compare the leucovorin rescue dose administered to the patients based on creatinine clearance, with the one calculated according to serum MTX levels, and (3) to determine MTX-related toxicity. PROCEDURE: Thirty children with high-risk non-B acute lymphoblastic leukemia (ALL) treated according to the national protocol (PINDA 92) based on ALL BFM 90, were randomized to receive consolidation with four doses of either 1 or 2 g/m(2) MTX as a 24-hr infusion, at 2-week intervals (group M1 and M2, respectively). Serum MTX concentrations were measured at 24, 42, and 48 hr after beginning the infusion and were analyzed retrospectively. The creatinine clearance was calculated after 12-hr intravenous hydration prior to each MTX dose. Leucovorin dosage was adjusted according to creatinine clearance. RESULTS: Serum MTX concentrations at 24, 42, and 48 hr after starting the infusion were not related to creatinine clearance in both treatment groups. Leucovorin rescue administered according to creatinine clearance was excessive in 43% in group M1 and in 51% in group M2, as compared to the dose calculated according to serum MTX levels. No serious clinical complications were observed. CONCLUSIONS: These results suggest that creatinine clearance is not a good parameter to calculate leucovorin rescue. MTX-related toxicity in this group of patients receiving a dose of 1 or 2 g/m(2) and rescued with leucovorin without monitoring serum MTX levels was acceptable. 相似文献
25.
Arnaud Scherpereel Julien Mazieres Laurent Greillier Sylvie Lantuejoul Pascal Dô Olivier Bylicki Isabelle Monnet Romain Corre Clarisse Audigier-Valette Myriam Locatelli-Sanchez Olivier Molinier Florian Guisier Thierry Urban Catherine Ligeza-Poisson David Planchard Elodie Amour Franck Morin Denis Moro-Sibilot Delphine CARMIER 《The lancet oncology》2019,20(2):239-253
26.
Olivier Rouvière Philippe Puech Raphaële Renard-Penna Michel Claudon Catherine Roy Florence Mège-Lechevallier Myriam Decaussin-Petrucci Marine Dubreuil-Chambardel Laurent Magaud Laurent Remontet Alain Ruffion Marc Colombel Sébastien Crouzet Anne-Marie Schott Laurent Lemaitre Muriel Rabilloud Nicolas Grenier 《The lancet oncology》2019,20(1):100-109
27.
Federica Medici Stefania Rizzo Milly Buwenge Alessandra Arcelli Martina Ferioli Gabriella Macchia Francesco Deodato Savino Cilla Pierandrea De Iaco Anna Myriam Perrone Silvia Strolin Lidia Strigari Gloria Ravegnini Alberto Bazzocchi Alessio G. Morganti 《Current oncology (Toronto, Ont.)》2022,29(11):8513
Sarcopenia (SP) is a syndrome characterized by age-associated loss of skeletal muscle mass and function. SP worsens both acute and late radiation-induced toxicity, prognosis, and quality of life. Myosteatosis is a pathological infiltration of muscle tissue by adipose tissue which often precedes SP and has a proven correlation with prognosis in cancer patients. Sarcopenic obesity is considered a “hidden form” of SP (due to large fat mass) and is independently related to higher mortality and worse complications after surgery and systemic treatments with worse prognostic impact compared to SP alone. The evaluation of SP is commonly based on CT images at the level of the middle of the third lumbar vertebra. On this scan, all muscle structures are contoured and then the outlined surface area is calculated. Several studies reported a negative impact of SP on overall survival in patients undergoing RT for tumors of the head and neck, esophagus, rectum, pancreas, cervix, and lung. Furthermore, several appetite-reducing side effects of RT, along with more complex radiation-induced mechanisms, can lead to SP through, but not limited to, reduced nutrition. In particular, in pediatric patients, total body irradiation was associated with the onset of SP and other changes in body composition leading to an increased risk of cardiometabolic morbidity in surviving adults. Finally, some preliminary studies showed the possibility of effectively treating SP and preventing the worsening of SP during RT. Future studies should be able to provide information on how to prevent and manage SP before, during, or after RT, in both adult and pediatric patients. 相似文献
28.
In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma 总被引:1,自引:0,他引:1
Valable S Barbier EL Bernaudin M Roussel S Segebarth C Petit E Rémy C 《NeuroImage》2008,40(2):973-983
This study has shown that murine monocytes/macrophages (Mo/Ma) can be labeled simply and efficiently with large, green-fluorescent, micrometer-sized particles of iron-oxide (MPIO). Neither size nor proliferation rate of the Mo/Ma is significantly affected by this labeling. The labeled Mo/Ma have been administered intravenously to rats that had developed a glioma following stereotactic injection of C6 cells. The labeled Mo/Ma were shown to target the brain tumors, a process that could be monitored non-invasively using T2*-weighted MRI. MRI observations were confirmed by Prussian blue staining, lectin staining and fluorescence histology. Overall, the results of this study suggest that the use of Mo/Ma may be envisaged in the clinic for vectorizing therapeutic agents toward gliomas. 相似文献
29.
Ricard Navins Giovanni Oriolo Igor Horrillo Myriam Cavero Bruno Aouizerate Martin Schaefer Lucile Capuron J Javier Meana Rocio Martin-Santos 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2022,25(6):468
BackgroundThe relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD).MethodsWe included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-Åsberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, C-reactive protein (CRP), and high-density lipoprotein cholesterol (HDL)-C levels. Treatment response was defined as ≥50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response.ResultsTwenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R2 = 0.457, P = .001), while S100B was at week 8 (R2 = 0.239, P = .011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement.ConclusionsSerum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers. 相似文献
30.
Monica Poiani Myriam Labopin Giorgia Battipaglia Dietrich W. Beelen Johanna Tischer Jürgen Finke Arne Brecht Edouard Forcade Arnold Ganser Jakob R. Passweg Helene Labussiere‐Wallet Ibrahim Yakoub‐Agha Kerstin Schfer‐Eckart Nicolaus Kroeger Blandine Guffroy Annalisa Ruggeri Jordi Esteve Arnon Nagler Mohamad Mohty 《American journal of hematology》2021,96(1):40-50
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo‐HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel‐Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC‐UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000‐2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow‐up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia‐free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3‐ITD mutation also remains a negative prognostic factor in this population. 相似文献